Elizabeth Macintyre
A5071962621- Acute Lymphoblastic Leukemia research
- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
- CAR-T cell therapy research
- Immune Cell Function and Interaction
- T-cell and Retrovirus Studies
- Viral-associated cancers and disorders
- Childhood Cancer Survivors' Quality of Life
- Epigenetics and DNA Methylation
- Celiac Disease Research and Management
- Immunodeficiency and Autoimmune Disorders
- Cancer Genomics and Diagnostics
- T-cell and B-cell Immunology
- Microscopic Colitis
- Retinoids in leukemia and cellular processes
- Glycosylation and Glycoproteins Research
- Eosinophilic Disorders and Syndromes
- Protein Degradation and Inhibitors
- Cancer-related gene regulation
- Sarcoma Diagnosis and Treatment
- Health Systems, Economic Evaluations, Quality of Life
- Histone Deacetylase Inhibitors Research
- Monoclonal and Polyclonal Antibodies Research
Université Paris Cité
2016-2025
Assistance Publique – Hôpitaux de Paris
2016-2025
Inserm
2016-2025
Institut Necker Enfants Malades
2016-2025
Hôpital Necker-Enfants Malades
2016-2025
Centre National de la Recherche Scientifique
2003-2024
Sorbonne Paris Cité
2012-2024
European Hematology Association
2022-2024
Carol Davila University of Medicine and Pharmacy
2023
Aalborg University Hospital
2023
We have previously shown correction of X-linked severe combined immunodeficiency [SCID-X1, also known as gamma chain (gamma(c)) deficiency] in 9 out 10 patients by retrovirus-mediated gamma(c) gene transfer into autologous CD34 bone marrow cells. However, almost 3 years after therapy, uncontrolled exponential clonal proliferation mature T cells (with gammadelta+ or alphabeta+ cell receptors) has occurred the two youngest patients. Both patients' clones showed retrovirus vector integration...
Previously, several individuals with X-linked SCID (SCID-X1) were treated by gene therapy to restore the missing IL-2 receptor gamma (IL2RG) CD34+ BM precursor cells using gammaretroviral vectors. While 9 of 10 patients successfully treated, 4 developed T cell leukemia 31-68 months after therapy. In 2 these cases, blast contained activating vector insertions near LIM domain-only (LMO2) proto-oncogene. Here, we report data on most recent adverse events, which occurred in 7 and 10. patient 10,...
Since the publication of Revised European-American Classification Lymphoid Neoplasms in 1994, subsequent updates classification lymphoid neoplasms have been generated through iterative international efforts to achieve broad consensus among hematopathologists, geneticists, molecular scientists, and clinicians. Significant progress has recently made characterization malignancies immune system, with many new insights provided by genomic studies. They led this proposal. We followed same process...
Most consensus leukemia & lymphoma antibody panels consist of lists markers based on expert opinions, but they have not been validated. Here we present the validated EuroFlow 8-color for immunophenotyping hematological malignancies. The single-tube screening and multi-tube classification fit into diagnostic algorithm with entries defined by clinical laboratory parameters. were constructed in 2-7 sequential design-evaluation-redesign rounds, using novel Infinicyt software tools multivariate...
Retrospective comparisons have suggested that adolescents or teenagers with acute lymphoblastic leukemia (ALL) benefit from pediatric rather than adult chemotherapy regimens. Thus, the aim of present phase II study was to test a pediatric-inspired treatment, including intensified doses nonmyelotoxic drugs, such as prednisone, vincristine, L-asparaginase, in patients ALL up age 60 years.Between 2003 and 2005, 225 (median age, 31 years; range, 15 years) Philadelphia chromosome-negative were...
Chromosomal rearrangements of the human MLL (mixed lineage leukemia) gene are associated with high-risk infant, pediatric, adult and therapy-induced acute leukemias. We used long-distance inverse-polymerase chain reaction to characterize chromosomal rearrangement individual leukemia patients. present data molecular characterization 1590 MLL-rearranged biopsy samples obtained from The precise localization genomic breakpoints within involved translocation partner genes (TPGs) were determined...
Amplicon-based next-generation sequencing (NGS) of immunoglobulin (IG) and T-cell receptor (TR) gene rearrangements for clonality assessment, marker identification quantification minimal residual disease (MRD) in lymphoid neoplasms has been the focus intense research, development application. However, standardization validation a scientifically controlled multicentre setting is still lacking. Therefore, IG/TR assay design, including bioinformatics, was performed within EuroClonality-NGS...
Purpose The Group for Research in Adult Acute Lymphoblastic Leukemia (GRAALL) recently reported a significantly better outcome T-cell acute lymphoblastic leukemia (T-ALL) harboring NOTCH1 and/or FBXW7 (N/F) mutations compared with unmutated T-ALL. Despite this, one third of patients N/F-mutated T-ALL experienced relapse. Patients and Methods In series 212 adult T-ALLs included the multicenter randomized GRAALL-2003 -2005 trials, we searched additional N/K-RAS PTEN defects (mutations gene...
Abstract Patients with Wiskott–Aldrich syndrome (WAS) lacking a human leukocyte antigen-matched donor may benefit from gene therapy through the provision of gene-corrected, autologous hematopoietic stem/progenitor cells. Here, we present comprehensive, long-term follow-up results (median follow-up, 7.6 years) (phase I/II trial no. NCT02333760 ) for eight patients WAS having undergone phase lentiviral vector-based trials (nos. NCT01347346 and NCT01347242 ), focus on thrombocytopenia...